A number of other analysts have also weighed in on NOVN. Baader Bank set a CHF 90 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Tuesday, October 24th. Barclays PLC set a CHF 75 price target on shares of Novartis AG and gave the company a sell rating in a research report on Wednesday, October 25th. S&P Global set a CHF 87 price target on shares of Novartis AG and gave the company a neutral rating in a research report on Tuesday, October 24th. UBS AG set a CHF 78 price target on shares of Novartis AG and gave the company a neutral rating in a research report on Monday, October 23rd. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on shares of Novartis AG and gave the company a neutral rating in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of CHF 86.10.
Novartis AG (NOVN) traded up 0.98% during midday trading on Monday, hitting CHK 82.40. 2,471,339 shares of the stock traded hands. The company has a market cap of CHK 193.05 billion and a price-to-earnings ratio of 30.08. The firm’s 50-day moving average is CHK 83.24 and its 200-day moving average is CHK 80.41. Novartis AG has a 52-week low of CHK 67.40 and a 52-week high of CHK 85.40.
ILLEGAL ACTIVITY WARNING: “Novartis AG (NOVN) Given a CHF 90 Price Target at HSBC Holdings plc” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/10/31/novartis-ag-novn-given-a-chf-90-price-target-at-hsbc-holdings-plc.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.